Novartis Advances Phase 3 Trial of Ianalumab, a BAFF-R Targeting Antibody for Immune Thrombocytopenia Treatment
Ianalumab's Differentiated Dual Mechanism Targeting BAFF-R
Ianalumab (VAY736) is the first fully human monoclonal antibody designed to target the B-cell activating factor receptor (BAFF-R), differentiating it from existing treatments for immune thrombocytopenia (ITP). This antibody strongly binds to BAFF-R on B cells, directly inducing B-cell depletion and blocking the interaction between BAFF and its receptor, thereby inhibiting the survival and activation of residual B cells. While current ITP treatments rely on simple immunosuppression with corticosteroids, Ianalumab aims to address the underlying cause of the disease by directly modulating the B cells that produce autoantibodies, garnering significant attention from the scientific community.
Strategic Core of the VAYHIT1 Phase 3 Trial Design
The ongoing VAYHIT1 (NCT05653349) Phase 3 trial evaluates the safety and efficacy of Ianalumab in combination with first-line standard therapy (corticosteroids) in 226 adult patients with primary ITP. This randomized, double-blind study has a primary endpoint of time to treatment failure (TTF). Patients will be observed to determine how long platelet counts remain at a safe level of 30 G/L after receiving Ianalumab in combination with corticosteroids, compared to those receiving corticosteroids alone. This proactive approach of administering a potent biological agent early in the treatment course aims to prevent progression to chronic ITP and maximize long-term efficacy.
Synergy with Previously Demonstrated VAYHIT2 Success
Novartis previously announced top-line results from the VAYHIT2 Phase 3 trial in August 2025, which evaluated Ianalumab in combination with Eltrombopag (Promacta) in a second-line treatment setting, demonstrating a statistically significant reduction in the risk of treatment failure. The efficacy data from VAYHIT2 provides strong indirect evidence supporting the potential success of the VAYHIT1 trial, and serves as a positive signal for Novartis's development of its hematology pipeline. By addressing both first-line (VAYHIT1) and second-line (VAYHIT2) treatment areas through two distinct clinical trial designs, Novartis aims to establish a clear leadership position in the ITP treatment market.
Novartis's Portfolio Evergreening and Market Expansion Strategy
The global ITP treatment market is estimated at $3.3 billion to $4 billion in 2025 and is a rapidly growing area with the introduction of new targeted therapies. Novartis already has a blockbuster drug, Eltrombopag, but to mitigate the impact of patent expiration, it is introducing Ianalumab as a follow-up immunomodulatory agent. If VAYHIT1 is successful and positive data is obtained before the expected completion date of September 2028, Novartis can accelerate the planned global regulatory submission in 2027. This will allow Novartis to seamlessly transition to the next generation of immunotherapies, driving corporate value to the next level while naturally inheriting the existing Eltrombopag market.
Novartis's Ianalumab is a promising pipeline asset poised to lead the shift towards next-generation immunomodulatory therapies in the global ITP treatment market, estimated at $3.3 to $4 billion in 2025. The ongoing Phase 3 trial, VAYHIT1 (NCT05653349), differentiates itself from competing drugs such as Sanofi's BTK inhibitor Rilzabrutinib or Argenx's FcRn inhibitor Vyvgart, which primarily target the second-line setting, by proactively introducing a dual-mechanism BAFF-R targeting antibody in the first-line treatment. In the medium to long term, combined with the top-line success of the VAYHIT2 trial in August 2025, it aims for global regulatory submission in 2027, making it a key element in Novartis's evergreen strategy to defend against the patent expiration risk of its existing blockbuster product, Eltrombopag, and solidify its market dominance. From the perspective of researchers and industry stakeholders, the demonstration of the clinical safety of this novel immunomodulatory mechanism, which simultaneously induces B-cell depletion and BAFF-R receptor inhibition, will be a critical factor in determining the potential for expansion to other autoimmune diseases such as lupus or Sjögren's syndrome.
Source: ClinicalTrials.gov (api_ct)